Now showing items 1-3 of 3

    • Antipsychotic Profile of Cannabidiol and Rimonabant in an Animal Model of Emotional Context Processing in Schizophrenia 

      Levin, Raquel [UNIFESP]; Almeida, Valeria [UNIFESP]; Peres, Fernanda Fiel [UNIFESP]; Calzavara, Mariana Bendlin [UNIFESP]; Silva, Neide Derci da [UNIFESP]; Suiama, Mayra Akimi [UNIFESP]; Niigaki, Suzy Tamie [UNIFESP]; Zuardi, Antonio Waldo [UNIFESP]; Hallak, Jaime Eduardo Cecilio; Crippa, Jose Alexandre de Souza; Abilio, Vanessa Costhek [UNIFESP] (Bentham Science Publ Ltd, 2012-11-01)
      Objectives: Clinical and neurobiological findings suggest that cannabinoids and their receptors are implicated in schizophrenia. Cannabidiol (CBD), a non-psychotomimetic compound of the Cannabis sativa plant, has been ...
    • Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test 

      Almeida, Valéria de [UNIFESP]; Levin, Raquel [UNIFESP]; Peres, Fernanda Fiel [UNIFESP]; Niigaki, Suzy Tamie [UNIFESP]; Calzavara, Mariana Bendlin [UNIFESP]; Zuardi, Antonio Waldo; Hallak, Jaime Eduardo Cecilio; Crippa, José Alexandre de Souza; Abílio, Vanessa Costhek [UNIFESP] (Elsevier B.V., 2013-03-05)
      Cannabidiol (CBD), a non-psychotomimetic compound of the Cannabis sativa, has been reported to have central therapeutic actions, such as antipsychotic and anxiolytic effects. We have recently reported that Spontaneously ...
    • Why we should use long-acting injectable antipsychotics more frequently 

      Maia-de-Oliveira, João Paulo; Bressan, Rodrigo Affonseca [UNIFESP]; Elkis, Helio; Machado-de-Sousa, João Paulo; Hallak, Jaime Eduardo Cecilio (Associação Brasileira de Psiquiatria - ABP, 2013-09-01)